James J. Harding, MD, provides a high-level overview of systemic therapy for untreated unresectable hepatocellular carcinoma (uHCC) based on NCCN Guidelines, and discusses the evolving treatment landscape, including the rationale for combination immunotherapy (IO) and how additional IO combinations may address unmet needs like depth of response and resistance.
Video content above is prompted by the following:
Give a high-level overview of systemic therapy for untreated uHCC
Briefly dDiscuss the evolving treatment landscape of systemic therapy in untreated uHCC.